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Aspergillus fumigatus is a human pathogen but it is also a widespread filamentous
fungus in the environment. A. fumigatus can therefore be exposed to antifungals
used in medical and agricultural environments. Only the class of azoles is used in
both of these environments (i.e. voriconazole and itraconazole in medicine;
prochloraz, propiconazole or imazalil in agriculture). Exposure to azoles provides
the potential for the development of resistance. Several clinical itraconazole-
resistant isolates have been reported in A. fumigatus and their resistance
mechanisms have been partially resolved. Since limited data exist on the
susceptibility of A. fumigatus to both medical and agricultural antifungals, we
undertook a drug susceptibility study including clinical (400) and agricultural (150)
A. fumigatus isolates (Swiss origin). We tested azoles and also compounds of major
antifungal classes used in agriculture (i.e. azoxystrobin, iprodione, benalaxyl or
cyprodinil). The results showed that all A. fumigatus isolates were intrinsically
resistant to iprodione, benalaxyl or cyprodinil (MIC90/32 mg / ml1) and that
azoxystrobin minimal inhibitory concentrations (MICs) showed a wide range (0.06
to 32 mg / ml1). MIC ranges of azoles were compound-dependent. MIC90 for
voriconazole, itraconazole, imazalil and prochloraz were within a range of 0.13 to
1 mg / ml1 and similar between clinical and environmental isolates, whereas
propiconazole was the least active compound (MIC90: 4/8 mg / ml1). Ten clinical
and 36 environmental isolates with high itraconazole MIC (]/2 mg / ml1) were
detected. In clinical isolates, no cross-resistance was observed between itraconazole
and all others azoles tested. Several patterns of azole MICs were, however,
observed in the environmental isolates. Unexpectedly, a single environmental
isolate was voriconazole-resistant (MIC of 16 mg / ml1) but still susceptible to
itraconazole (MIC of 2 mg / ml1). Taken together, our results demonstrate the
absence of susceptibility of A. fumigatus isolates to non-azole agricultural agents
and that there is little impact of azole resistance in both clinical and environmental
isolates. When detected, azole resistance was compound-specific.
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Introduction
Aspergillus fumigatus is one of the most prevalent
airbone fungal pathogens, causing severe fatal invasive
aspergillosis in immunocompromised patients [1]. It is
also found in the environment as a plant contaminant
or participates in the degradation of organic material
present in compost sites.
A few antifungal agents are available for the
treatment of aspergillosis in humans. All these anti-
fungal agents belong to one of three groups, the
polyenes (amphotericin B), the azoles (itraconazole and
voriconazole), and the echinocandins (caspofungin).
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Among antifungal agents used in the environment for
crop protection, the class of azoles is also widely used
(e.g. propiconazole, prochloraz, or imazalil). Other
agents belonging to the class of dicarboximides (which
affects cell division, DNA and RNA metabolism;
iprodione is a specific agent of this class), phenylamides
(which affects RNA synthesis; e.g. benalaxyl), anilipyr-
imides (which inhibits amino acid biosynthesis; e.g.
cyprodinil) or axoxystrobin (which inhibits mitochon-
drial respiration) are also used. Given the ubiquity of
A. fumigatus in the environment, these isolates are
often exposed to the agricultural antifungals. In the
environment, antifungal agents (such as imazalil, pro-
chloraz, azoxystrobin) can be detected. Fruit and
vegetables have been shown to contain substantial
amount of these agents (between 0.01/5 mg.kg1)
[2,3].
Itraconazole or voriconazole are widely used to treat
aspergillosis in patients, with moderate success [4].
Emergence of resistance to these antifungals might be
expected among clinical A. fumigatus isolates owing to
their increasing use, if the source of patient isolates is
directly or indirectly from other patient isolates.
Indeed, a selection pressure due to the presence of
antifungal agents can lead to a genetic adaptation
resulting in a resistant strain. However, only a limited
number of clinical isolates showing itraconazole resis-
tance have been described [5]. Whereas the mechanisms
of resistance to azoles have been well investigated in
Candida albicans isolates [6/8], few detailed studies
have been performed on antifungal resistance in
A. fumigatus. Up to now, mutations in the gene
encoding the azole target, Cyp51A , have been detected
in itraconazole-resistant isolates [9]. In our laboratory,
several experiments have been performed that suggest
that the expression of ATP-Binding Cassette transpor-
ter (ABC transporters) and Major Facilitator genes
also contributes to itraconazole resistance [D. San-
glard, unpublished data]. Since almost no data exist in
Switzerland on the status of antifungal susceptibility of
A. fumigatus, we undertook evaluation of the in vitro
activity of several antifungal agents on isolates using
both medical (itraconazole, voriconazole and ampho-
tericin B) and agricultural (prochloraz, propiconazole,
imazalil, azoxystrobin, iprodione, benalaxyl and cypro-
dinil) agents. Minimal inhibitory concentrations (MIC)
results were determined by a microdilution standard
protocol according to the National Committee for
Clinical Laboratory Standards (NCCLS MP38-A) on
400 clinical isolates from patients hospitalized in
several major Swiss hospitals and on 150 isolates
from several environmental sites (compost sites, vine-
yards, crop areas) around Switzerland. This method
has proven to be useful for in vitro susceptibility testing
in A. fumigatus [10].
Material and methods
Organisms
All clinical strains of A. fumigatus were evaluated from
our current collection of 400 strains. They were all
isolated from hospitalized patients with various forms
of A. fumigatus infection from major Swiss hospitals
(80 isolates from University Hospital of Zurich; 250
from University Hospital of Lausanne; 45 from Uni-
versity Hospital of Geneva and 25 from Istituto
Cantonale di Microbiologia). Moreover, 150 environ-
mental A. fumigatus isolates were obtained from
different sites in Switzerland (crop areas, vineyards,
compost sites). All Aspergillus isolates were plated to
obtain individual colonies. Individual colonies were
propagated on slopes of Sabouraud agar for a perma-
nent culture collection in our laboratory and stored at
/48C.
Antifungal agents
In order to carry out the in vitro susceptibility tests,
pure compounds were obtained from their respective
manufacturers. Agricultural antifungal agents (i.e.
axoxystrobin, imazalil, prochloraz and propiconazole,
iprodione, benalaxyl, or cyprodinil) were provided by
Dr. Ehrenstorfer GmbH (Augsburg, Germany). Am-
photericin B was from Bristol-Myers Squibb (Baar,
Switzerland). Itraconazole and voriconazole were from
CilagAG (Shaffhausen, Switzerland) and Pfizer (Sand-
wich, UK), respectively. Itraconazole, voriconazole,
amphotericin B, azoxystrobin, and propiconazole
were dissolved in dimethyl sulfoxide (DMSO, Fluka),
prochloraz in acetone, and imazalil in ethanol, at a
concentration of 10 mg.ml1, except for itraconazole
which was dissolved in DMSO in order to obtain a
1.6 mg.ml1 stock solution. All drugs were stored at
/208C.
Preparation of conidial suspensions
Conidia were obtained by growth of isolates on
Sabouraud agar at 378C for 3/4 days. Conidia were
collected by flooding the agar surfaces with phosphate-
buffered saline and 0.05% Tween80 (Fluka) and
viability was determined for each isolate. The number
of CFU per ml was determined by plating different
volumes of an appropriate diluted cell suspension
(106) on Sabouraud agar. Inoculum of 7/105 viable
spores per ml were prepared.
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Media for antifungal susceptibility testing
The standard RPMI 1640 (Diagnostic Medical Dis-
tribution, Zurich, Switzerland) contained 0.2% glucose,
and 0.165 M MOPS (morpholine propane sulfonic
acid) buffer to a pH of 7.0. The Antibiotic Medium 3
(AM3) broth was prepared according to the instruc-
tions of the manufacturer (Difco, Detroit, Michigan).
Amphotericin B MICs were determined using AM3
medium; RPMI 1640 was used for all other antifungal
agents.
Antifungal susceptibility testing
We used the microdilution broth method according
NCCLS (M38-A) guidelines for in vitro susceptibility
testing. The stock conidial suspension was diluted in
RPMI 1640 or in AM3 medium according to the
antifungal agent used. A fixed amount of A. fumigatus
conidia was also used [11]. First, 150 ml of drug
free medium was dispensed into each well of the
96 well plates (Costar). Serial two-fold dilutions
of each antifungal agent were prepared with the
appropriate medium (RPMI 1640 or AM3) (dilutions
ranged from 0.02 to 16 mg / ml1). To prepare a
drug dilution series, starting solutions of the drug
were dispensed in 50 ml of medium into the first
well of the plate. Two-fold dilutions were then
performed to yield expected drug concentrations.
Aliquots of 50 ml of the stock conidial suspension
were then added to the wells. The final volume in
each well was to 200 ml and the final concentrat-
ion of the inoculum was 1.8/105 conidia per ml. The
plates were incubated for two days at 378C after which
visual readings were performed. The MIC was defined
as the lowest concentration of drug that completely
inhibited fungal growth. MIC50 or MIC90 values
correspond to antifungal concentrations that inhibit
50% or 90% of the isolates from a tested collection.
Results and discussion
Preliminary experiments on a subset of clinical and
environmental A. fumigatus isolates showed that they
were intrinsically resistant to iprodione, benalaxyl or
cyprodinil (MIC90/32 mg / ml1); therefore, further
testing of these antifungal agents with the remaining
collection was abandoned. Table 1 summarizes the in
vitro susceptibilities of 400 A. fumigatus clinical isolates
and of 150 agricultural isolates against all the remain-
ing antifungal agents tested except for azoxystrobin, a
strobulin agent. Even though azoxystrobin MICs
showed a wide distribution (0.06 to 32 mg / ml1),
azoxytrobin was the least active antifungal agent with
a MIC90 of 32 mg / ml1. In general, azoles derivatives
showed a wide distribution of MIC across similar
concentration ranges (from 0.02 to 16 mg / ml1).
MIC90 values of the medical azole antifungals
(voriconazole, itraconazole) were within a range of
0.5 to 2 mg / ml1 in both clinical and environmental
isolates. With MIC90 values of 1 and 0.5 mg / ml1 for
clinical and agricultural isolates, respectively, vorico-
nazole was slightly more active than itraconazole,
which had MIC90 values of 1 and 2 mg / ml1 for
clinical and environmental isolates, respectively. Am-
photericin B was the medical antifungal agent with the
lowest activity: MIC90 values of 4 mg / ml1 were
measured in both clinical and environmental isolates.
Several studies performed on clinical isolates have
reported in vitro activities of medical antifungal agents
close to those measured in this study. MIC90 of 0.5, 0.5
and 2 mg / ml1 for itraconazole, voriconazole and
amphotericin B, respectively, were reported [12]. MIC90
of 2 and 1 mg / ml1 for itraconazole and amphotericin
B were measured in a separate study [13]. Among the
agricultural azoles tested, propiconazole was the least
active compound (MIC90 value of 8 mg / ml1) in both
clinical and environmental isolates; MIC90 of imazalil
and prochloraz were lower in environmental isolates
(0.13 for imazalil and 0.25 mg / ml1 for prochloraz,
Table 1 In vitro susceptibility to six antifungal agents of Aspergillus fumigatus clinical (400) and environmental (150) isolates.
Drug MIC range (mg / /ml1)(a) MIC distribution
Clinical isolates Environmental isolates Clinical isolates Environmental isolates
MIC50 MIC90 MIC50 MIC90
Itraconazole 0.03/16 0.06/16 0.5 1 0.5 2
Voriconazole 0.03/4 0.06/16 0.25 1 0.25 0.5
Amphotericin B 0.06/8 0.5/8 1 4 2 4
Imazalil 0.08/2 0.02/0.5 0.13 0.5 0.06 0.13
Prochloraz 0.02/8 0.02/16 0.13 1 0.06 0.25
Propiconazole 0.03/16 0.5/32 2 8 4 8
(a) MIC range and MIC distribution are given for both clinical and environmental isolates and for each antifungal agent tested.
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respectively) than in clinical isolates (0.5 mg / ml1 for
imazalil and 1 mg / ml1 for prochloraz, respectively).
Isolates with high itraconazole MIC (MIC
]/2 mg / ml1) were detected in both clinical (total of
10 isolates) and environmental isolates (total of 36).
Antifungals MICs of only a selection of these isolates
are shown in Table 2. These high itraconazole MICs
were not strictly accompanied with a higher MIC to the
all other azole antifungals listed in Table 2. For
example, the environmental isolate AFenv51 showed
an itraconazole MIC value of ]/16 mg / ml1; vorico-
nazole, imazalil and prochloraz had MICs of 1, 0.06
and 1 mg / ml1, respectively. However, isolate
AFenv119 had an itraconazole MIC of 2 mg / ml1;
voriconazole, imazalil and prochloraz had MICs of 2, 8
and 16 mg / ml1, respectively. The MIC profile of
isolate AFenv155 was however similar to AFenv119,
with the exception of the prochloraz MIC]/16
mg / ml1. Clinical isolates with itraconazole MIC]/2
mg / ml1 were less heterogeneous in their azole MIC
patterns. The voriconazole MICs of these isolates
remained at 0.5 mg / ml1, which is the value observed
for most of the itraconazole-susceptible isolates. The
MIC profiles shown in Table 2 for selected clinical
isolates are in agreement with reports documenting no
cross-resistance with voriconazole [9,14]. This absence
of cross-resistance mainly between itraconazole and
voriconazole can be attributed to their differences in
chemical structure (Fig. 1). Indeed, azoles block
ergosterol synthesis in A. fumigatus by binding to their
target enzyme, the 14a-demethylase Cyp51A . Since
voriconazole is a relatively compact molecule as
compared to itraconazole with its extended side chain,
binding does not involve the same residues. A study
Table 2 Antifungal MIC patterns of environmental and clinical Aspergillus fumigatus isolates with high itraconazole MIC.
MIC (mg / ml1)
Itraconazole Voriconazole Imazalil Prochloraz Propiconazole Amphotericin B
AFenv51 a) ]/16 1 0.06 1 ]/16 1
AFenv110 4 0.13 0.13 0.13 8 8
AFenv115 4 0.13 0.06 0.13 4 4
AFenv135 8 0.25 0.13 0.13 8 8
AFenv149 4 0.5 0.13 0.25 16 4
AFenv119 2 2 8 16 8 4
‘‘typical isolate’’ 0.13 0.25 0.03 0.06 2 2
AFenv155 2 16 8 /16 16 4
AFL16.1 b) 2 0.5 0.25 0.13 8 2
AFL12.1 2 0.5 0.13 1 4 1
AFL50.7 2 0.5 0.5 1 4 4
AFL30.1 4 0.5 0.13 0.13 4 2
AFL35.9 16 0.5 0.13 0.06 4 1
‘‘typical isolate’’ 0.25 0.5 0.25 0.5 8 2
a) AFenvxx, A. f
¯
umigatus Environment isolate xx in our nomenclature collection.
b) AFLxx.y, A. f
¯
umigatus from L
¯
ausanne, patient xx, isolate y.
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Fig. 1 Chemical structures of voriconazole (A) and itraconazole (B).
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suggests that the long side chain of itraconazole occupy
a specific channel within Cyp51 and that, this addi-
tional interaction should stabilize its binding to the
mutated CYP51 proteins [15] mutations known to
confer itraconazole resistance [9]. Therefore, the differ-
ent binding sites of azoles in the target enzyme could
explain the absence of cross-resistance between itraco-
nazole and voriconazole.
More surprising are results obtained with isolates
from the environment, where cross-resistance between
itraconazole and voriconazole could be measured and
where the MIC patterns were more heterogenous. These
data suggest that the mechanisms responsible for the
MIC increase in specific azole might have different
origins and will be the focus of future studies in our
laboratory.
Taken together, ours results show:
1. Absence of susceptibility of Aspergillus fumigatus
isolates to non-azole agricultural agents with an
intrinsic resistance to agents such as benalaxyl,
cyprodinil and iprodione, and
2. Very little impact of azole resistance in both clinical
and environmental isolates.
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